ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
— Existing investors and new investor Double Point Ventures join forces to support ImmunOs Therapeutics
— Investment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers
ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its unique immune system modulating HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of a Series C financing round of $11 million. The round was led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners and supported by new investor Double Point Ventures as well as other existing investors. In conjunction with the round, Steve Tregay, PhD, Managing General Partner of Mission BioCapital, has joined the Company’s Board of Directors.
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
— Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA®
ImmunOs Therapeutics AG, a biopharmaceutical company using its HLA-based technology platform to develop first-in-class and innovative therapeutics for the treatment of cancer and autoimmune diseases, today announced the expansion of its ongoing Phase I clinical trial of IOS-1002 in combination with MSD (Merck & Co., Inc., Rahway, NJ, USA)’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) for the treatment of advanced solid tumors.
BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients
— Favorable safety profile of resorbable breast scaffolds in one-year follow-up
— No major scaffold-related complications or scaffold removals
— BellaSeno will initiate multicenter pivotal clinical trial with more than 100 patients
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that 10 breast scaffold patients and 5 pectus patients have successfully passed one-year follow-up in BellaSeno´s Australian clinical trials.
